For greater than a half century, dopaminergic dysregulation has been implicated in AD and other disinhibitory psychopathology. Molecular genetics studies over the past 20 years have attempted to demonstrate associations with DA genes and disinhibitory phenotypes, producing an inconsistent and controversial literature. Meta-analyses, reviews, and reports with rigorous methodology suggest that variation in DA genes does contribute to susceptibility to disinhibitory traits, although not to the extent and effect size originally hypothesized.
